JP2005530716A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530716A5
JP2005530716A5 JP2003579755A JP2003579755A JP2005530716A5 JP 2005530716 A5 JP2005530716 A5 JP 2005530716A5 JP 2003579755 A JP2003579755 A JP 2003579755A JP 2003579755 A JP2003579755 A JP 2003579755A JP 2005530716 A5 JP2005530716 A5 JP 2005530716A5
Authority
JP
Japan
Prior art keywords
fragment
polynucleotide
polypeptide
medicament
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530716A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/009707 external-priority patent/WO2003082212A2/en
Publication of JP2005530716A publication Critical patent/JP2005530716A/ja
Publication of JP2005530716A5 publication Critical patent/JP2005530716A5/ja
Pending legal-status Critical Current

Links

JP2003579755A 2002-03-27 2003-03-27 ヒトにおける癌の治療方法 Pending JP2005530716A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36843802P 2002-03-27 2002-03-27
PCT/US2003/009707 WO2003082212A2 (en) 2002-03-27 2003-03-27 Method for treating cancer in humans

Publications (2)

Publication Number Publication Date
JP2005530716A JP2005530716A (ja) 2005-10-13
JP2005530716A5 true JP2005530716A5 (https=) 2006-01-12

Family

ID=28675491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579755A Pending JP2005530716A (ja) 2002-03-27 2003-03-27 ヒトにおける癌の治療方法

Country Status (6)

Country Link
US (2) US20050063947A1 (https=)
EP (1) EP1589990B1 (https=)
JP (1) JP2005530716A (https=)
AU (1) AU2003226141A1 (https=)
CA (1) CA2481304A1 (https=)
WO (1) WO2003082212A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
DK1531850T3 (da) * 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
EP1573006B1 (en) 2002-12-13 2009-11-11 ZymoGenetics, Inc. Il-21 production in prokaryotic hosts
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
JP2007508332A (ja) * 2003-10-17 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ 併用療法
EP2641611A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
WO2005052139A2 (en) * 2003-11-19 2005-06-09 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method of inducing memory b cell development and terminal differentiation
CA2604222A1 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
MX2007015039A (es) * 2005-06-06 2008-01-24 Novo Nordisk As Composiciones de il-21 estabilizadas.
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
US8211420B2 (en) 2006-12-21 2012-07-03 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
US20080267910A1 (en) * 2007-03-09 2008-10-30 Wu Paul W Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences
CN102387808A (zh) 2009-02-20 2012-03-21 有限公司名将 免疫增强组成物及其制造方法
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
KR20230145241A (ko) * 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
GB201816547D0 (en) 2018-10-10 2018-11-28 Univ London Queen Mary Oncolytic virus for the treatment of cancer
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69332197T2 (de) * 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1082433A4 (en) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins 21 and 22
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6312924B1 (en) * 1999-03-18 2001-11-06 Zymogenetics, Inc. Murine interferon-α
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
CA2418014C (en) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia
WO2002072796A2 (en) * 2001-03-12 2002-09-19 Cellcure Aps Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity
ES2629395T3 (es) * 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans

Similar Documents

Publication Publication Date Title
JP2005530716A5 (https=)
Chabalgoity et al. The relevance of cytokines for development of protective immunity and rational design of vaccines
Lin et al. Therapeutic hpv DNA vaccines
Masihi Fighting infection using immunomodulatory agents
Wilke et al. Dual biological effects of the cytokines interleukin-10 and interferon-γ
Zlotnik et al. Interleukin 10
EP1589990B1 (en) Il-21 for use in treating cancer
JP2006141398A5 (https=)
RU2000131593A (ru) Селективные агонисты и антагонисты il-2.
JP2006020648A5 (https=)
Tan et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model
US20230053010A1 (en) Methods of Treating Glioblastoma
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
CA2282300A1 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
HUP0402259A2 (hu) Vakcinák
Shurin et al. Antitumor activities of IL-12 and mechanisms of action
Namkoong et al. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11
Agha-Mohammadi et al. Immunomodulation of cancer: potential use of selectively replicating agents
Mikysková et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
Zhang et al. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.
Wang et al. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes
JP2006502228A5 (https=)
JP2005512518A5 (https=)
JP2004507445A (ja) 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法